Fish Oil Triglycerides Meta-analysis: What the Evidence Says

Quick Answer

Fish Oil Triglycerides Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 narrative review, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• 1 15 16 15 2 16 17 18 Most of the increased morbidity and mortality associated with CKD is attributable to CVD with an increased risk beginning with both mildly reduced estimated glomerular filtration rate (eGFR) and very low levels of albuminuria (albumin: creatinine ratio >30 mg/g). [Ferro Charles J (2026); evidence level 3]
• This risk increases exponentially and independently with worsening eGFR and albuminuria with the highest risk being observed in individuals with severely reduced eGFR and high levels of albuminuria. [Ferro Charles J (2026); evidence level 3]
• Over time, however, increased rates of exaggerated inflammatory responses began to be reported in critically ill patients and in individuals receiving long-term parenteral nutrition, and excessive omega-6 fatty-acid delivery was considered a likely contributor to these adverse effects. [Kęska Mariusz (2026); evidence level 4]
• This article is a narrative review that aims to synthesize the mechanistic rationale and clinically relevant evidence regarding fish oil-containing injectable lipid emulsions (FO-ILE) used in parenteral nutrition (PN), with a focus on critically ill adult patients. [Kęska Mariusz (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For fish oil triglycerides meta-analysis, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Ferro Charles J (2026). Fish oil supplements in patients with chronic kidney disease. DOI: 10.1093/ckj/sfag168. PMCID: PMC13261989. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13261989/
• Kęska Mariusz (2026). Fish Oil-Containing Injectable Lipid Emulsions in Parenteral Nutrition: Immunomodulation and Clinical Outcomes in Critically Ill Patients—Narrative Review. DOI: 10.3390/nu18060939. PMCID: PMC13029142. PMID: 41901114. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13029142/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.